Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

  • Min Wu Chao (Contributor)
  • Li Hsun Chang (Contributor)
  • Huang Ju Tu (Contributor)
  • Chao-Di Chang (Contributor)
  • Mei-Jung Lai (Contributor)
  • Ying Yi Chen (Creator)
  • Jing-Ping Liou (Creator)
  • Che Ming Teng (Contributor)
  • Shiow-Lin Pan (Contributor)



Figure S2. MEK inhibitors downregulate HDAC inhibitor-induced p-ERK and EGFR expression. (A) PANC-1 cells were treated with 5 μM MPT0E028 or SAHA combined with or without 20 μM PD98059 (PD) for 72 h. The protein expression of p-ERK and EGFR was determined by western blotting. t-ERK was used as an internal control. PANC-1 (B) and BxPC-3 (C) cells were treated with indicated conditions for 48 h to determine EGFR mRNA expression. *P 
Date made available2019

Cite this